You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCisplatin
Accession NumberDB00515  (APRD00359)
TypeSmall Molecule
GroupsApproved
DescriptionCisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Structure
Thumb
Synonyms
CDDP
Cis-DDP
cis-diamminedichloroplatinum(II)
Platinol-AQ
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CisplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2012-01-13Not applicableUs
CisplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2012-01-13Not applicableUs
CisplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2015-04-15Not applicableUs
Cisplatin Inj 0.5mg/mlLiquid.5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Cisplatin Inj 1mg/mlLiquid1 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1986-12-311998-08-13Canada
Cisplatin InjectionSolution1.0 mgIntravenousTeva2013-08-29Not applicableCanada
Cisplatin InjectionSolution1 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Cisplatin InjectionSolution1 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Cisplatin InjectionSolution1 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Cisplatin Injection BPSolution1 mgIntravenousHospira, Inc.1997-05-09Not applicableCanada
Cisplatin Injection BPSolution1 mgIntravenousSandoz Canada Incorporated2011-09-29Not applicableCanada
Cisplatin Injection, BPSolution1 mgIntravenousAccord Healthcare Limited2012-04-10Not applicableCanada
Cisplatin Injection, Mylan Std.Solution1 mgIntravenousMylan Pharmaceuticals2013-06-122016-07-06Canada
PlatinolInjection, powder, lyophilized, for solution1 mg/mLIntravenousCorden Pharma Latina S.p.A.2012-01-13Not applicableUs
Platinol AQ Inj 1mg/mlLiquid1 mgIntravenousBristol Labs Division Of Bristol Myers Squibb1988-12-312001-07-30Canada
Platinol-AQInjection, solution1 mg/mLIntravenousCorden Pharma Latina S.p.A.2012-01-13Not applicableUs
PMS-cisplatinSolution1 mgIntravenousPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CisplatinInjection1 mg/mLIntravenousBlue Point Laboratories2016-08-02Not applicableUs
CisplatinInjection1 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-04-19Not applicableUs
CisplatinInjection, solution1 mg/mLIntravenousFresenius Kabi2000-09-05Not applicableUs
CisplatinInjection1 mg/mLIntravenousAccord Healthcare Limited2016-03-01Not applicableUs
CisplatinInjection1 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-04-19Not applicableUs
CisplatinInjection1 mg/mLIntravenousMylan Institutional2012-04-19Not applicableUs
CisplatinInjection, solution50 mg/50mLIntravenousTeva Parenteral Medicines, Inc.2000-06-01Not applicableUs
CisplatinInjection1 mg/mLIntravenousMylan Institutional2012-04-19Not applicableUs
CisplatinInjection, solution100 mg/100mLIntravenousTeva Parenteral Medicines, Inc.2000-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbiplatinNot Available
CisplatylNot Available
PlatidiamNot Available
PlatinCadila Healthcare
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ20Q21Q62J
CAS number15663-27-1
WeightAverage: 298.035
Monoisotopic: 296.939928001
Chemical FormulaCl2H4N2Pt
InChI KeyDQLATGHUWYMOKM-UHFFFAOYSA-L
InChI
InChI=1S/2ClH.2H2N.Pt/h2*1H;2*1H2;/q;;2*-1;+4/p-2
IUPAC Name
dichloroplatinumdiamine
SMILES
N[Pt](N)(Cl)Cl
Pharmacology
IndicationFor the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingDiagnosticHead and Neck Cancers1
0Active Not RecruitingTreatmentCancer of Head and Neck1
0CompletedPreventionGastric Cancers / Gastro-esophageal Junction Cancer / Stomach Cancer1
0CompletedTreatmentHead and Neck Cancers1
0CompletedTreatmentHead and Neck Cancers / Pharynx Cancer1
0RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
0RecruitingTreatmentPancreatic Adenocarcinoma1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
1Active Not RecruitingTreatmentCholangiocarcinoma of the Gallbladder / Localized Gallbladder Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Hereditary Breast/Ovarian Cancer - BRCA1 / Hereditary Breast/Ovarian Cancer - BRCA2 / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Neoplasm / Fallopian Tube Transitional Cell Carcinoma / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Tumor / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Tumor / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentHead and Neck Cancers1
1Active Not RecruitingTreatmentHuman Papillomavirus Infections / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1Active Not RecruitingTreatmentLeukemias / Lymphoma NOS1
1Active Not RecruitingTreatmentLung Cancers3
1Active Not RecruitingTreatmentLymphoma NOS1
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentMetastatic Malignant Neoplasm in the Lung / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Adult Soft Tissue Sarcoma / Stage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentNeoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)1
1Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid2
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)3
1Active Not RecruitingTreatmentStomach Neoplasms1
1Active Not RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedNot AvailableCancer, Ovarian / Head and Neck Cancers / Lung Cancers / Neurotoxicity1
1CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinomas / Adrenocortical Carcinoma / Desmoplastic Small Round Cell Tumor (DSRCT) / Neoplasms, Gastrointestinal / Neoplasms, Ovarian / Neuroblastomas / Peritoneal Neoplasms / Retroperitoneal Neoplasms / Rhabdomyosarcomas / Sarcomas / Wilms Tumor1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentBiliary Tract Cancer1
1CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
1CompletedTreatmentBrenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentCancer of Parotid / Head and Neck Cancers / Malignant Neoplasm of Thyroid / Melanoma / Stage IV Head and Neck Cancer1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Cancers / Lung Cancers / Mesothelioma / Pancreatic Cancers / Prostate Cancers / Sarcomas1
1CompletedTreatmentCancer, Breast / Melanoma (Skin) / Prostate Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer2
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancer, Ovarian / Head and Neck Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers4
1CompletedTreatmentCancers / Tumors, Solid1
1CompletedTreatmentCarcinomas / Peritoneal Neoplasms1
1CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer2
1CompletedTreatmentCervical Adenocarcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
1CompletedTreatmentCervical Cancers5
1CompletedTreatmentCervix Cancer1
1CompletedTreatmentChemotherapeutic Agent Toxicity / Endometrial Adenocarcinomas / Fallopian Tube Carcinoma / Gastrointestinal Complications / Malignant Ovarian Mixed Epithelial Tumor / Neurotoxicity Syndrome / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage II Ovarian Cancer / Stage III Ovarian Cancer / Stage IV Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentColorectal Cancers / Lung Cancers1
1CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Cancers1
1CompletedTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEsophageal Cancers2
1CompletedTreatmentEsophageal Cancers / Gastric Cancers1
1CompletedTreatmentEsophageal Cancers / Gastric Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentFallopian Tube Adenocarcinoma / Ovarian Adenocarcinoma / Primary Peritoneal Carcinoma1
1CompletedTreatmentGastric Cancers2
1CompletedTreatmentGastric Cancers / Pancreatic Cancers1
1CompletedTreatmentGastric cancer stage IV / Stomach Neoplasms1
1CompletedTreatmentHEAD & NECK Cancer1
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHead and Neck Cancers4
1CompletedTreatmentHead and Neck Cancers / Laryngeal Cancer / Oral Cancers / Pharyngeal Cancer / Squamous Carcinoma1
1CompletedTreatmentHead and Neck Cancers / Squamous Cell Carcinoma (SCC)1
1CompletedTreatmentHepatocellular Carcinomas / Liver Cancer / Localized Unresectable Liver Cancer1
1CompletedTreatmentInoperable Locally Advanced or Metastatic Biliary Tract Cancer1
1CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV1
1CompletedTreatmentLung Cancer, Non-Small Cell1
1CompletedTreatmentLung Cancers9
1CompletedTreatmentLymphoma NOS / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMesothelioma2
1CompletedTreatmentMesothelioma, Malignant1
1CompletedTreatmentMetastatic Cancers / Tumors, Solid1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentNeoplasms3
1CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1CompletedTreatmentNeoplasms, Head and Neck1
1CompletedTreatmentNeoplasms, Malignant2
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentNeuroblastomas / Sarcomas / Tumor, Brain / Tumors, Central Nervous System1
1CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
1CompletedTreatmentPancreatic Cancers1
1CompletedTreatmentRecurrent Cervical Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer / Stage III Vaginal Cancer / Stage IIIA Cervical Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Vulvar Cancer / Stage IIIB Cervical Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Vulvar Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Vulvar Cancer / Stage IV Ovarian Epithelial Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Cervical Cancer / Stage IVB Vaginal Cancer1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentSolid Tumors or Mantle Cell Lymphoma1
1CompletedTreatmentStage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1CompletedTreatmentStage IV Melanoma1
1CompletedTreatmentStomach Neoplasms3
1CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
1CompletedTreatmentTumors, Solid4
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific21
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers1
1Not Yet RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
1Not Yet RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Vulvar Cancer / Stage IB2 Cervical Cancer / Stage II Vulvar Cancer / Stage IIA1 Cervical Cancer / Stage IIA2 Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIA Vulvar Cancer / Stage IIIB Cervical Cancer / Stage IIIB Vulvar Cancer / Stage IIIC Vulvar Cancer / Stage IVA Cervical Cancer / Stage IVA Vulvar Cancer / Vulvar Adenocarcinoma / Vulvar Squamous Cell Carcinoma1
1Not Yet RecruitingTreatmentHead and Neck Cancer Metastatic / Head or Neck Cancer / Recurrent Head and Neck Carcinoma1
1Not Yet RecruitingTreatmentLocoregionally Advanced / Squamous Cell Carcinoma of Head and Neck1
1Not Yet RecruitingTreatmentPleural Mesotheliomas1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingBasic ScienceNeoplasms1
1RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Gallbladder / Duct Cell Adenocarcinoma of the Pancreas / Localized Unresectable Adult Primary Liver Cancer / Periampullary Adenocarcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Gallbladder Cancer / Recurrent Pancreatic Cancer / Stage II Gallbladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IV Pancreatic Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer1
1RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1RecruitingTreatmentAdult Solid Neoplasm / Metastatic Pancreatic Adenocarcinoma / Pancreatic Adenocarcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1RecruitingTreatmentAdvanced Solid Tumors2
1RecruitingTreatmentAmpullary Cancer / Biliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
1RecruitingTreatmentBile Duct Cancer / Carcinoma of Gallbladder / Carcinoma of Intrahepatic and Extra-hepatic Biliary System / Cholangiocarcinomas1
1RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureter Cancer / Urethra Cancer1
1RecruitingTreatmentCancer of Nasopharynx / Carcinoma of Larynx / Carcinoma, Squamous Cell of Head and Neck / Early Invasive Cervical Squamous Cell Carcinoma / HPV Positive Oropharyngeal Squamous Cell Carcinoma / Hypopharyngeal Cancer1
1RecruitingTreatmentCancer, Advanced / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCancer, Ovarian1
1RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1RecruitingTreatmentCancers2
1RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
1RecruitingTreatmentCervical Carcinoma1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentEsophageal Cancers1
1RecruitingTreatmentHNSCC1
1RecruitingTreatmentHead and Neck Cancers2
1RecruitingTreatmentHead and Neck Cancers / Hypopharynx Cancer / Laryngeal Cancer / Larynx Cancer / Oral Cavity Cancer / Oropharynx Cancers / Squamous Cell Carcinoma (SCC)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Metastatic Pancreatic Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma1
1RecruitingTreatmentHepatic Complications1
1RecruitingTreatmentInoperable Locally Advanced Non Small Cell Lung Cancer1
1RecruitingTreatmentLocally Advanced Nasopharyngeal Carcinoma1
1RecruitingTreatmentLung Cancers3
1RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1RecruitingTreatmentMetastatic Disease1
1RecruitingTreatmentMetastatic Malignant Neoplasm in the Brain / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Lung Adenocarcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Lung Adenocarcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Large Cell Lung Carcinoma / Stage IV Lung Adenocarcinoma / Stage IV Non-Small Cell Lung Cancer1
1RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Lung1
1RecruitingTreatmentNeoplasms, Head and Neck1
1RecruitingTreatmentNon-Small Cell Lung Cancer, Small Cell Lung Cancer / Platinum Responsive Malignancies1
1RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentOncology, Medical1
1RecruitingTreatmentPleural Effusion, Malignant1
1RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1RecruitingTreatmentStage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1RecruitingTreatmentStage IV Lung Adenocarcinoma1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUrothelial Carcinoma of the Urinary Bladder1
1SuspendedNot AvailableCarcinoma, Squamous Cell of Head and Neck1
1SuspendedTreatmentCancers1
1SuspendedTreatmentCarcinoma Neuroendocrine / Malignant Epithelial Neoplasms / Small Cell Lung Carcinoma1
1SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1SuspendedTreatmentStage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer1
1TerminatedNot AvailableCancers1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1TerminatedTreatmentAdult Solid Neoplasm1
1TerminatedTreatmentAdvanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Bladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Transitional Cell Carcinoma of the Bladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
1TerminatedTreatmentBladder Cancers / Tumors, Solid1
1TerminatedTreatmentCervix Cancer1
1TerminatedTreatmentEsophageal Cancers1
1TerminatedTreatmentEsophageal Cancers / Lung Cancers / Pancreatic Cancers1
1TerminatedTreatmentHead and Neck Cancers1
1TerminatedTreatmentLung Cancer, Non-Small Cell1
1TerminatedTreatmentLung Cancers / Non-Small-Cell Lung Cancer (NSCLC) / Tumors, Solid1
1TerminatedTreatmentLung Metastases / Osteosarcomas1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1TerminatedTreatmentNonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung1
1TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1TerminatedTreatmentSalivary Gland Squamous Cell Carcinoma / Stage II Salivary Gland Cancer / Stage II Squamous Cell Carcinoma of the Hypopharynx / Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage II Verrucous Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Verrucous Carcinoma of the Oral Cavity1
1TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
1TerminatedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnNot AvailableLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)1
1WithdrawnTreatmentAdult Solid Neoplasm / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentCervical Cancers3
1WithdrawnTreatmentEpithelial Ovarian Carcinoma / Ovarian Carcinoma, Stage 3 or 4 / Primary Peritoneal Carcinoma1
1WithdrawnTreatmentHead and Neck Cancers / Lip and Oral Cavity Cancer / Oropharyngeal Cancers1
1WithdrawnTreatmentLung Cancers2
1WithdrawnTreatmentLymphoma NOS1
1WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
1WithdrawnTreatmentMucositis / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
1WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer / Tumors, Solid1
1WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1WithdrawnTreatmentRecurrent Ovarian Carcinoma1
1WithdrawnTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Active Not RecruitingSupportive CareDrug/Agent Toxicity by Tissue/Organ / Head and Neck Cancers / Radiation Toxicity1
1, 2Active Not RecruitingSupportive CareHead and Neck Cancers / Mucositis1
1, 2Active Not RecruitingTreatmentAdvanced Biliary Tract Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Malignant Mesothelioma / Epithelioid Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma1
1, 2Active Not RecruitingTreatmentAnaplastic Thyroid Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentBiliary Tract Neoplasms / Cholangiocarcinomas / Gallbladder Neoplasms1
1, 2Active Not RecruitingTreatmentBladder Cancers / Carcinoma, Urothelial1
1, 2Active Not RecruitingTreatmentCancer, Breast2
1, 2Active Not RecruitingTreatmentCarcinoma of Unknown Primary Origin / Carcinoma, Small Cell / Extensive Stage Small Cell Lung Carcinoma / Large Cell Lung Carcinoma / Neuroendocrine Carcinomas / Newly Diagnosed Carcinoma of Unknown Primary Origin / Stage IV Non-Small Cell Lung Cancer1
1, 2Active Not RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
1, 2Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers1
1, 2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
1, 2Active Not RecruitingTreatmentGastric Cancers / Histone Deacetylase Inhibitor1
1, 2Active Not RecruitingTreatmentHead and Neck Cancers3
1, 2Active Not RecruitingTreatmentMalignant Tumor of Renal Pelvis / Transitional Cell Carcinoma of Bladder / Ureter Cancer / Urethra Cancer1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1, 2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1, 2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentSmall Cell Lung Carcinoma1
1, 2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2CompletedTreatmentAdvanced Cervical Cancer1
1, 2CompletedTreatmentAdvanced Squamous Cell Carcinoma / Squamous Cell Carcinoma of Head and Neck / SSCHN1
1, 2CompletedTreatmentBiliary Tract Cancer1
1, 2CompletedTreatmentBladder Cancers2
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
1, 2CompletedTreatmentCancer of Head and Neck / Head and Neck Cancers / Head Cancer / Neck Cancer / Neoplasms, Neck1
1, 2CompletedTreatmentCancer of the Cervix1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
1, 2CompletedTreatmentCarcinoma of Head and/or Neck / Squamous Cell Carcinoma (SCC)1
1, 2CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Cancers1
1, 2CompletedTreatmentCarcinoma, Small Cell1
1, 2CompletedTreatmentCervical Cancers2
1, 2CompletedTreatmentCervical Cancers / Radiation Toxicity1
1, 2CompletedTreatmentCholangiocellular Carcinoma1
1, 2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
1, 2CompletedTreatmentEsophageal Cancers2
1, 2CompletedTreatmentEsophageal Cancers / Esophagogastric Junction Adenocarcinoma / Gastric Cancers1
1, 2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer / Lung Cancers / Small Cell Lung Cancer (SCLC) / Tumors, Solid1
1, 2CompletedTreatmentGastric Cancers1
1, 2CompletedTreatmentGastric cancer stage IV1
1, 2CompletedTreatmentHead and Neck Cancers5
1, 2CompletedTreatmentHepatocellular Carcinomas1
1, 2CompletedTreatmentLung Cancers5
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Tumors, Solid1
1, 2CompletedTreatmentMalignant Pleural Mesotherioma1
1, 2CompletedTreatmentMetastasis / Neoplasms, Colorectal1
1, 2CompletedTreatmentMetastatic Melanoma2
1, 2CompletedTreatmentNeoplasm, Gastric1
1, 2CompletedTreatmentNeoplasms, Head and Neck1
1, 2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
1, 2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentPancreatic Cancers1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
1, 2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentSquamous Cell Cancer1
1, 2CompletedTreatmentTransitional Cell Carcinoma1
1, 2CompletedTreatmentUrologic Neoplasms1
1, 2CompletedTreatmentUterine Cervical Cancer1
1, 2Not Yet RecruitingTreatmentGastric cancer stage IV1
1, 2Not Yet RecruitingTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Not Yet RecruitingTreatmentNeoplasms, Oropharyngeal / Oropharyngeal Cancers / Squamous Carcinoma / Squamous Cell Carcinoma (SCC)1
1, 2RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentAdvanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Solid Neoplasms / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Ovarian Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Pleural Mesothelioma / Thymoma1
1, 2RecruitingTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2RecruitingTreatmentCancer, Breast / Triple-Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentCervical Cancers1
1, 2RecruitingTreatmentCholangiocarcinomas2
1, 2RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentGastric Carcinoma1
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Salivary Gland Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
1, 2RecruitingTreatmentLocally Advanced Cervical Cancer1
1, 2RecruitingTreatmentLung Cancers2
1, 2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2RecruitingTreatmentNasopharyngeal Carcinoma1
1, 2RecruitingTreatmentNeoplasms, Esophageal1
1, 2RecruitingTreatmentNeoplasms, Head and Neck1
1, 2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentPancreatic Cancers1
1, 2RecruitingTreatmentRecurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer1
1, 2RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentStage IV Pancreatic Cancer1
1, 2RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2TerminatedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Squamous Cell Carcinoma of the Esophagus / Stage III Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2TerminatedTreatmentAdvanced or Metastatic Solid Tumors / Previously Untreated Gastric Cancer1
1, 2TerminatedTreatmentBowel Obstruction / Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
1, 2TerminatedTreatmentCarcinoma, Small Cell1
1, 2TerminatedTreatmentCarcinoma, Small Cell / SCLC / Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentCervical Cancers1
1, 2TerminatedTreatmentEstrogen Receptor Negative Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentGastric Cancers1
1, 2TerminatedTreatmentHead and Neck Cancers3
1, 2TerminatedTreatmentHead and Neck Cancers / Squamous Cell Cancer1
1, 2TerminatedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1, 2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingNot AvailableRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingNot AvailableTumors, Solid1
2Active Not RecruitingDiagnosticLung Cancers1
2Active Not RecruitingPreventionPulmonary Relapse of Osteosarcoma1
2Active Not RecruitingSupportive CareDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2Active Not RecruitingTreatmentAcquired Immunodeficiency Syndromes / Cervical Cancers1
2Active Not RecruitingTreatmentAdvanced Breast Cancer1
2Active Not RecruitingTreatmentAdvanced Cancers / Sarcomas1
2Active Not RecruitingTreatmentAdvanced Malignant Pleural Mesothelioma1
2Active Not RecruitingTreatmentAnal Cancer2
2Active Not RecruitingTreatmentBiliary Cancer / Pancreatic Cancers1
2Active Not RecruitingTreatmentBladder Cancers3
2Active Not RecruitingTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2Active Not RecruitingTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
2Active Not RecruitingTreatmentBladder Cancers / Urachal Cancer / Urethral Cancer1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors3
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2Active Not RecruitingTreatmentCancer of Head / Cancer of Head and Neck / Cancer of Neck / Cancer of the Head / Cancer of the Neck / Cancers of the Head and Neck / Head and Neck Cancers / Head Cancer / Head, Neck Neoplasms / Neck Cancer / Neoplasms, Head / Neoplasms, Head and Neck / Neoplasms, Neck / Neoplasms, Upper Aerodigestive Tract / UADT Neoplasms1
2Active Not RecruitingTreatmentCancer, Breast6
2Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Metastatic Cancers / Peritoneal Cavity Cancer1
2Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Active Not RecruitingTreatmentCarcinoma, Urothelial1
2Active Not RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB2 Cervical Cancer / Stage II Vaginal Cancer / Stage IIA1 Cervical Cancer / Stage IIA2 Cervical Cancer / Stage IIB Cervical Cancer / Stage III Vaginal Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Vaginal Adenocarcinoma / Vaginal Adenosquamous Carcinoma / Vaginal Squamous Cell Carcinoma1
2Active Not RecruitingTreatmentCervical Cancers2
2Active Not RecruitingTreatmentCervical Cancers / Endometrial Cancers1
2Active Not RecruitingTreatmentChemoradiation / Neoplasms, Esophageal1
2Active Not RecruitingTreatmentDistal Urethral Cancer / Proximal Urethral Cancer / Squamous Cell Carcinoma of the Bladder / Stage II Bladder Cancer / Stage III Bladder Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2Active Not RecruitingTreatmentEsophageal Cancers6
2Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers2
2Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers / Stomach Cancer1
2Active Not RecruitingTreatmentEsophageal Cancers / Stomach Cancer1
2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
2Active Not RecruitingTreatmentGastric Cancers5
2Active Not RecruitingTreatmentGastric cancer stage IV1
2Active Not RecruitingTreatmentGastroesophageal Junction Neoplasms / Stomach Neoplasms1
2Active Not RecruitingTreatmentHead and Neck Cancers15
2Active Not RecruitingTreatmentHead and Neck Cancers / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentHepatocellular Carcinomas / Liver Cancer1
2Active Not RecruitingTreatmentLiver Cancer2
2Active Not RecruitingTreatmentLung Cancers8
2Active Not RecruitingTreatmentLymphoma NOS5
2Active Not RecruitingTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Osteosarcomas1
2Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingTreatmentMalignant Solid Tumors1
2Active Not RecruitingTreatmentMesothelioma, Malignant3
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma2
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck / Neoplasms, Oropharyngeal / Squamous Cell Carcinoma (SCC)1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentNon-Small Cell Lung Cancer Metastatic / Nonsquamous Nonsmall Cell Neoplasm of Lung1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
2Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentPancreatic Cancers2
2Active Not RecruitingTreatmentProstate Cancers1
2Active Not RecruitingTreatmentProsthesis Survival1
2Active Not RecruitingTreatmentRecurrent Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2Active Not RecruitingTreatmentRenal Cell Carcinoma (RCC)1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentStomach Neoplasms1
2Active Not RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2Approved for MarketingNot AvailableMesothelioma1
2CompletedNot AvailableMesothelioma1
2CompletedDiagnosticLymphoma NOS1
2CompletedPreventionCancers1
2CompletedPreventionOral Mucositis / Sarcomas1
2CompletedSupportive CareBrain and Central Nervous System Tumors1
2CompletedSupportive CareCancer, Breast / Cancer, Ovarian / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedSupportive CareCancers / Chemotherapy-Induced Thrombocytopenia / Lung Cancers / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Oncology / Thrombocytopenias / Tumors, Solid1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Head and Neck Cancers / Oral Complications / Radiation Toxicity1
2CompletedSupportive CareLymphoma NOS / Neutropenias1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of GE Junction / Adenocarcinoma of Stomach1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Squamous Cell Carcinoma of Esophagus1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of Oesophagus1
2CompletedTreatmentAdenocarcinoma of the Esophagus / Recurrent Esophageal Cancer / Stage IV Esophageal Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Stomach / Stage II Gastric Cancer / Stage III Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdrenocortical Carcinoma1
2CompletedTreatmentAdrenocortical Carcinoma / Brain and Central Nervous System Tumors / Head and Neck Cancers / Liver Cancer / Mesothelioma, Malignant / Pheochromocytomas / Sarcomas1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Localized Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentAnemias / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Neutropenias1
2CompletedTreatmentBRCA1 Mutations / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentBiliary Tract Cancer1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer1
2CompletedTreatmentBiliary Tract Carcinoma1
2CompletedTreatmentBladder Cancers8
2CompletedTreatmentBladder Cancers / Drug/Agent Toxicity by Tissue/Organ1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBladder Cancers / Urethral Cancer2
2CompletedTreatmentBladder Cancers / Urinary Bladder1
2CompletedTreatmentBone Metastases / Hormone Refractory Prostate Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors6
2CompletedTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Pediatric Germ Cell Tumor1
2CompletedTreatmentBrain and Central Nervous System Tumors / Head and Neck Cancers / Lymphoma NOS1
2CompletedTreatmentCancer of Cervix1
2CompletedTreatmentCancer of Head and Neck1
2CompletedTreatmentCancer of Head and Neck / Squamous Cell Cancer1
2CompletedTreatmentCancer of the Lung / Carcinomas / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentCancer of the Pancreatic Head1
2CompletedTreatmentCancer, Breast10
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Ovarian3
2CompletedTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Drug/Agent Toxicity by Tissue/Organ / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Colorectal Cancers / Gastric Cancers / Gastrointestinal Carcinoid Tumor / Gastrointestinal Stromal Tumors / Peritoneal Cavity Cancer / Small Intestine Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer2
2CompletedTreatmentCancers1
2CompletedTreatmentCancers / Head and Neck Cancers / Oncology / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma of Esophagus1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma, Non-Small-Cell Lung (NSCLC)1
2CompletedTreatmentCarcinoma, Non-Small-Cell-Lung Cancer1
2CompletedTreatmentCarcinoma, Urothelial1
2CompletedTreatmentCarcinomas / Nasopharyngeal Neoplasms1
2CompletedTreatmentCarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer1
2CompletedTreatmentCervical Cancers9
2CompletedTreatmentCervical Neoplasms1
2CompletedTreatmentConcomitant Radiochemotherapy / NSCLC Stage IIIB1
2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2CompletedTreatmentEarly Triple Negative Breast Cancer1
2CompletedTreatmentEffects of Chemotherapy / Malignant Neoplasm of Stomach1
2CompletedTreatmentEfficacy / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Cell Carcinoma / Endometrial Clear Cell Carcinoma / Endometrial Papillary Serous Carcinoma / Stage I Endometrial Carcinoma / Stage II Endometrial Carcinoma / Stage III Endometrial Carcinoma / Stage IV Endometrial Carcinoma1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEpithelial Ovarian Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentEsophageal Cancers12
2CompletedTreatmentEsophageal Cancers / Gastric Cancers / GE Junction Cancer1
2CompletedTreatmentEsophageal Cancers / Gastric Cancers9
2CompletedTreatmentEsophageal Carcinoma2
2CompletedTreatmentEwings Sarcoma / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer3
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour2
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentGastric Cancers16
2CompletedTreatmentGastric Cancers / Stomach Cancer1
2CompletedTreatmentGastric cancer stage IV2
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentGastrointestinal Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentGastrointestinal Carcinoid Tumor / Islet Cell Tumor1
2CompletedTreatmentGenital Neoplasms, Male1
2CompletedTreatmentGerm Cell Tumors / Testicular Neoplasms1
2CompletedTreatmentHead and Neck1
2CompletedTreatmentHead and Neck Cancers18
2CompletedTreatmentHead and Neck Cancers / Lung Cancers1
2CompletedTreatmentHead and Neck Cancers / Oral Complications of Radiation Therapy / Radiation Toxicity1
2CompletedTreatmentHead and Neck Cancers / Precancerous Conditions1
2CompletedTreatmentHead and Neck Cancers / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2CompletedTreatmentHepatocellular Carcinomas1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHypopharynx Cancer / Larynx Cancer1
2CompletedTreatmentKidney Cancer1
2CompletedTreatmentLarynx Carcinoma / Squamous Cell Carcinoma of the Hypopharynx1
2CompletedTreatmentLeptomeningeal Metastasis / Metastases, Brain / Neoplasms, Breast1
2CompletedTreatmentLeukemias / Lymphoma NOS1
2CompletedTreatmentLimited Stage Small Cell Lung Cancer1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLiver Cancer / Metastatic Cancers1
2CompletedTreatmentLung Adenocarcinoma / Metastases, Brain1
2CompletedTreatmentLung Cancer, Non-Small Cell1
2CompletedTreatmentLung Cancers23
2CompletedTreatmentLymphoma NOS9
2CompletedTreatmentMalignant Ascites / Malignant Pleural Effusions1
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)2
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2CompletedTreatmentMelanoma (Skin)2
2CompletedTreatmentMelanoma / Skin Cancers2
2CompletedTreatmentMesothelioma1
2CompletedTreatmentMesothelioma, Malignant4
2CompletedTreatmentMetastatic Breast Cancer (MBC)5
2CompletedTreatmentMetastatic Cancers / Sarcomas1
2CompletedTreatmentMetastatic Non-squamous Non Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Osteosarcoma1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentMetastatic / Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentNasopharyngeal Cancers2
2CompletedTreatmentNasopharyngeal Carcinoma2
2CompletedTreatmentNasopharyngeal Neoplasms2
2CompletedTreatmentNasopharyngeal Squamous Cell Carcinoma / Toxicity Due to Radiotherapy1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Gastrointestinal1
2CompletedTreatmentNeoplasms, Head and Neck4
2CompletedTreatmentNeoplasms, Lung2
2CompletedTreatmentNeoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNeoplasms, Squamous Cell1
2CompletedTreatmentNeuroblastomas5
2CompletedTreatmentNeuroblastomas / Tumor, Brain / Tumors, Central Nervous System1
2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)7
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)3
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)2
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)27
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
2CompletedTreatmentOesophageal Carcinoma1
2CompletedTreatmentOsteosarcomas1
2CompletedTreatmentPancreatic Cancers14
2CompletedTreatmentPenile Cancer2
2CompletedTreatmentPleural Neoplasms1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentRadiation Induced Mucositis in Head and Neck Cancer1
2CompletedTreatmentRecurrent Cervical Cancer / Recurrent Vaginal Cancer / Stage IB Cervical Cancer / Stage II Vaginal Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage III Vaginal Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Cervical Cancer / Stage IVB Vaginal Cancer / Therapy-Related Toxicity1
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Ovarian Cancer1
2CompletedTreatmentRecurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer1
2CompletedTreatmentResected Advanced Gastric Cancer1
2CompletedTreatmentRetinoblastoma1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)3
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck2
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
2CompletedTreatmentStage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2CompletedTreatmentStage III Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2CompletedTreatmentStage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentStage IV Nasopharyngeal Carcinoma1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentTesticular germ cell tumour1
2CompletedTreatmentThymoma1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentTumor, Brain / Tumors, Central Nervous System1
2CompletedTreatmentUrinary Tract Cancers1
2CompletedTreatmentUrothelial Cancer1
2CompletedTreatmentVulvar Cancers1
2Not Yet RecruitingTreatmentAdvanced Head and Neck Cancer1
2Not Yet RecruitingTreatmentBladder Cancers2
2Not Yet RecruitingTreatmentCancer of Head and Neck / Cancers of the Head and Neck / Carcinoma, Squamous Cell of the Head and Neck / Head and Neck Cancers / Neoplasms, Head and Neck / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentCervical Cancers1
2Not Yet RecruitingTreatmentDrug Therapy / Genes, EGFR / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2Not Yet RecruitingTreatmentLung Cancers1
2Not Yet RecruitingTreatmentMalignant Pleural Effusions1
2Not Yet RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma4
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma Head and Neck1
2Not Yet RecruitingTreatmentTriple-negative Metastatic Breast Cancer1
2Not Yet RecruitingTreatmentUnresectable Biliary Tract Cancer1
2RecruitingNot AvailableSeminoma1
2RecruitingDiagnosticSquamous Cell Carcinoma of Oropharynx1
2RecruitingDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2RecruitingPreventionGastric Cancers1
2RecruitingPreventionGastric cancer stage IV1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingPreventionNeoplasms, Head and Neck1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cancers1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Adenosquamous / Squamous Cell Carcinoma (SCC) / Uterine Cervical Neoplasms1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Lung1
2RecruitingTreatmentAdrenocortical Carcinoma / Peritoneal Carcinomatosis1
2RecruitingTreatmentAdvanced Esophageal Squamous Carcinoma1
2RecruitingTreatmentAdvanced or Recurrent Endometrial Cancer1
2RecruitingTreatmentAnal Basaloid Carcinoma / Anal Canal Cloacogenic Carcinoma / Anal Squamous Cell Carcinoma / Metastatic Anal Canal Carcinoma / Recurrent Anal Canal Carcinoma / Stage IIIB Anal Canal Cancer / Stage IV Anal Canal Cancer1
2RecruitingTreatmentAnal Canal Carcinoma1
2RecruitingTreatmentAnal Cancer1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Metastatic Pancreatic Adenocarcinoma / PALB2 Gene Mutation / Pancreatic Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentBevacizumab / Metastases, Brain / Non Squamous Non-small Cell Lung Cancer1
2RecruitingTreatmentBiliary Cancer1
2RecruitingTreatmentBiliary Carcinoma / Cholangiocarcinomas / Gall Bladder Carcinoma / Gastrointestinal Tumors1
2RecruitingTreatmentBiliary Tract Cancer3
2RecruitingTreatmentBiliary Tract Cancer / Cancer, Advanced / Metastatic Cancers1
2RecruitingTreatmentBiliary Tract Carcinoma / Gallbladder Carcinoma1
2RecruitingTreatmentBladder Cancers3
2RecruitingTreatmentBladder Cancers / Bladder Carcinoma / Muscle Invasive Bladder Carcinoma / Transition Cell Cancer1
2RecruitingTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2RecruitingTreatmentCancer of Head and Neck / Carcinoma, Squamous Cell of Head and Neck / Head and Neck Cancers / Neoplasms, Head and Neck / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma, Head And Neck1
2RecruitingTreatmentCancer, Breast3
2RecruitingTreatmentCancer, Breast / Metastases, Brain1
2RecruitingTreatmentCancer, Ovarian2
2RecruitingTreatmentCancers of the Head and Neck / Head and Neck Cancers / Head and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentCarcinoma, Urothelial1
2RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage IB2 Cervical Cancer / Stage II Vaginal Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Vaginal Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Vaginal Cancer1
2RecruitingTreatmentCervical Cancers6
2RecruitingTreatmentCholangiocarcinomas2
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)2
2RecruitingTreatmentDigestive System Neoplasms / Esophageal Cancers / Neoplasms / Neoplasms, Esophageal1
2RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentEpidermal Growth Factor Receptor (EGFR) Protein Overexpression / Malignant Neoplasm of Cardio-esophageal Junction of Stomach / Malignant Neoplasm of Stomach1
2RecruitingTreatmentEpithelial Ovarian Cancer / Fallopian Tube Cancer / Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2RecruitingTreatmentEsophageal Cancers4
2RecruitingTreatmentEsophageal Squamous Cell Carcinoma Resectable1
2RecruitingTreatmentEsophageal Squamous Cell Carcinomas4
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Peritoneal Carcinoma1
2RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentGastric Cancers2
2RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
2RecruitingTreatmentGastric Cancers / Neuroendocrine Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentGastric Junction Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentGastrointestinal Cancers1
2RecruitingTreatmentGerm Cell Tumors3
2RecruitingTreatmentHead and Neck Cancers7
2RecruitingTreatmentHead and Neck Cancers / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentHead and Neck Squamous Carcinoma / Nasopharyngeal Carcinoma1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentHepatocellular Carcinoma Non-resectable1
2RecruitingTreatmentHigh-Grade Gliomas1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentHuman Papilloma Virus Infection / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx2
2RecruitingTreatmentHypopharyngeal Cancer / Oropharyngeal Cancers1
2RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Cancer / Mucinous Breast Cancer / Tubular Breast Cancer1
2RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
2RecruitingTreatmentIntraocular Melanoma1
2RecruitingTreatmentLaryngeal Cancer1
2RecruitingTreatmentLocalized Squamous Cell Carcinoma of the Esophagus1
2RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2RecruitingTreatmentLocally Advanced Head and Neck Squamous Cell Carcinoma1
2RecruitingTreatmentLocally Recurrent/Metastatic Triple Negative Breast Cancer1
2RecruitingTreatmentLung Adenocarcinoma1
2RecruitingTreatmentLung Cancers5
2RecruitingTreatmentLung Neoplasms, Non-Small Cell Lung Cancer1
2RecruitingTreatmentLymphoma NOS2
2RecruitingTreatmentMalignant Gliomas1
2RecruitingTreatmentMalignant Pleural Effusions1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Mesothelioma1
2RecruitingTreatmentMalignant / Mesothelioma / Pleural1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMedulloblastomas / Neuroectodermal Tumors, Primitive / Tumor, Brain1
2RecruitingTreatmentMelanoma (Skin)1
2RecruitingTreatmentMesothelioma1
2RecruitingTreatmentMesothelioma, Malignant1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)3
2RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Urothelial Carcinoma1
2RecruitingTreatmentMyelomas1
2RecruitingTreatmentNasopharyngeal Cancers1
2RecruitingTreatmentNasopharyngeal Carcinoma6
2RecruitingTreatmentNasopharyngeal Neoplasms1
2RecruitingTreatmentNasophayngeal Carcinoma Between Stage II and IVb1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Head and Neck1
2RecruitingTreatmentNeoplasms, Head and Neck / Neoplasms, Oropharyngeal / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
2RecruitingTreatmentNon-HPV Locally Advanced Head and Neck Cancer1
2RecruitingTreatmentNon-Small Cell Lung Cancer Metastatic1
2RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)2
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)6
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA1
2RecruitingTreatmentOvarian Granulosa Cell Tumor / Ovarian Gynandroblastoma / Ovarian Sertoli-Leydig Cell Tumors / Ovarian Sex Cord Tumor With Annular Tubules / Ovarian Sex Cord-Stromal Tumor / Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types / Ovarian Steroid Cell Tumor1
2RecruitingTreatmentPancreatic Cancers1
2RecruitingTreatmentParanasal Sinus Neoplasms / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentPatients Diagnosed With Advanced Carcinoma of Uterine Cervix t1
2RecruitingTreatmentPeritoneal Carcinomatosis1
2RecruitingTreatmentRecurrent Head and Neck Cancer1
2RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
2RecruitingTreatmentRecurrent / Stage IV / Stomach Neoplasms1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
2RecruitingTreatmentSmall Cell Lung Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2RecruitingTreatmentSquamous Cell Carcinoma of the Anus1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
2RecruitingTreatmentSquamous Cell Carcinoma of the Head / Squamous Cell Carcinoma of the Neck1
2RecruitingTreatmentSquamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Larynx Stage III / Squamous Cell Carcinoma of the Larynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV / Squamous Cell Carcinoma of the Oropharynx Stage III / Squamous Cell Carcinoma of the Oropharynx Stage IV1
2RecruitingTreatmentSquamous Cell Esophageal Carcinoma1
2RecruitingTreatmentSquamous Cell Lung Cancer1
2RecruitingTreatmentStage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2RecruitingTreatmentStage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
2RecruitingTreatmentStage IV Nasopharyngeal Carcinoma1
2RecruitingTreatmentStomach Neoplasms1
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentUnresectable Intrahepatic Cholangiocarcinoma1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2RecruitingTreatmentUrinary Bladder Neoplasms1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2SuspendedTreatmentStage IIIA Vulvar Cancer / Stage IIIB Vulvar Cancer / Stage IIIC Vulvar Cancer / Stage IVA Vulvar Cancer / Vulvar Squamous Cell Carcinoma1
2SuspendedTreatmentTesticular Cancer1
2TerminatedDiagnosticMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2TerminatedSupportive CareCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Neurotoxicity / Primary Peritoneal Cavity Cancer / Sarcomas1
2TerminatedSupportive CareChemotherapeutic Agent Toxicity / Mucositis / Radiation Toxicity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Xerostomia1
2TerminatedSupportive CareNausea and Vomiting / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Adenocarcinomas1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cancers1
2TerminatedTreatmentAnxiety Disorder / Depression / Lethargy / Lung Cancers1
2TerminatedTreatmentBile Duct Cancer / Cancer of Gallbladder / Cholangiocarcinomas / Hepatobiliary Neoplasms / Liver Cancer1
2TerminatedTreatmentBile Duct Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocellular Carcinoma / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Hepatocellular Carcinomas / Periampullary Adenocarcinoma1
2TerminatedTreatmentBladder Cancers4
2TerminatedTreatmentCancer of Larynx1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentCancers / Melanoma1
2TerminatedTreatmentCardiac Toxicity / Sarcomas1
2TerminatedTreatmentCervical Cancers2
2TerminatedTreatmentDrug/Agent Toxicity by Tissue/Organ / Head and Neck Cancers / Oral Complications / Radiation Toxicity1
2TerminatedTreatmentEsophageal Cancers5
2TerminatedTreatmentEsophageal Cancers / Gastric Adenocarcinoma / Gastric Cancers1
2TerminatedTreatmentEsophageal Diseases1
2TerminatedTreatmentFallopian Tube Cancer / Recurrent Ovarian Cancer1
2TerminatedTreatmentGastric Cancers1
2TerminatedTreatmentHead and Neck Cancers5
2TerminatedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2TerminatedTreatmentLaryngeal Neoplasms / Mouth Neoplasms / Neoplasms, Head and Neck / Pharyngeal Neoplasms1
2TerminatedTreatmentLocally Advanced Biliary Tract Cancer / Metastatic Biliary Tract Cancer1
2TerminatedTreatmentLoco-regional Esophageal Cancer1
2TerminatedTreatmentLower Oesophagus Cancer / Oesophageal Junction Cancer / Stomach Neoplasms1
2TerminatedTreatmentLung Cancers7
2TerminatedTreatmentMedulloblastomas / Primitive Neuroectodermal Tumor / Tumor, Brain / Tumors, Central Nervous System1
2TerminatedTreatmentMelanoma1
2TerminatedTreatmentMesothelioma, Malignant1
2TerminatedTreatmentMesothelioma / Pleural Mesotheliomas1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentNeoplasms, Oropharyngeal1
2TerminatedTreatmentNeoplasms, Pancreatic / Pancreatic Cancers1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentNon-Small Cell Lung Cancer Metastatic1
2TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)2
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Stage IIIA (N2)1
2TerminatedTreatmentNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentOral Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentPancreatic Cancers2
2TerminatedTreatmentSarcomas3
2TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1
2TerminatedTreatmentSmall Cell Lung Carcinoma1
2TerminatedTreatmentThymic Carcinoma / Thymoma1
2TerminatedTreatmentTransitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentUterine Cervical Cancer1
2TerminatedTreatmentUterine Neoplasms1
2WithdrawnTreatmentAdenocarcinomas / Carcinomas / Uterine Cervix Adenosquamous Carcinoma1
2WithdrawnTreatmentAdult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS-Related1
2WithdrawnTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureter Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentCervical Cancers1
2WithdrawnTreatmentCervical Cancers / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
2WithdrawnTreatmentHead and Neck Cancers3
2WithdrawnTreatmentHepatocellular Carcinomas1
2WithdrawnTreatmentHuman Papilloma Virus (HPV) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentLymphoma NOS1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentSmall Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2WithdrawnTreatmentStage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Tongue Cancer1
2WithdrawnTreatmentTransitional Cell Carcinoma1
2WithdrawnTreatmentTumors, Solid1
2WithdrawnTreatmentUnknown Primary Tumors1
2, 3Active Not RecruitingTreatmentEsophageal Cancers1
2, 3Active Not RecruitingTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2, 3Active Not RecruitingTreatmentGastric Cancers1
2, 3Active Not RecruitingTreatmentHead and Neck Cancers1
2, 3Active Not RecruitingTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2, 3CompletedTreatmentAdenocarcinomas / Esophageal Cancers1
2, 3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2, 3CompletedTreatmentBiliary Tract Neoplasms1
2, 3CompletedTreatmentCisplatin Adverse Reaction / Upper GI Cancer1
2, 3CompletedTreatmentEsophageal Cancers2
2, 3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2, 3CompletedTreatmentHead and Neck Cancers1
2, 3CompletedTreatmentLung Cancers1
2, 3CompletedTreatmentNeoplasm Recurrence, Local / Neoplasms Metastasis / Neoplasms, Head and Neck1
2, 3CompletedTreatmentPancreatic Cancers2
2, 3Not Yet RecruitingNot AvailableNasopharyngeal Carcinoma1
2, 3Not Yet RecruitingTreatmentHuman Papillomavirus (HPV)-Positive Oropharyngeal Cancer1
2, 3Not Yet RecruitingTreatmentMesothelioma1
2, 3RecruitingTreatmentActivating EGFR Mutation / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-squamous Non-small Cell Lung Cancer Stage II / Non-squamous Non-small Cell Lung Cancer Stage IIIA / Non-squamous Non-small Cell Lung Cancer Stage IIIB1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentCancers / Cisplatin Adverse Reaction1
2, 3RecruitingTreatmentCervical Cancers1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentEpstein-Barr Virus Infections / Stage II Nasopharyngeal Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IVA Nasopharyngeal Carcinoma / Stage IVB Nasopharyngeal Carcinoma1
2, 3RecruitingTreatmentEsophageal Cancers1
2, 3RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
2, 3RecruitingTreatmentEsophageal Squamous Cell Carcinomas1
2, 3RecruitingTreatmentGastric Cancers / Peritoneal Carcinomatosis1
2, 3RecruitingTreatmentHepatocellular Carcinomas1
2, 3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Cancer / Mucinous Breast Cancer / Tubular Breast Cancer1
2, 3RecruitingTreatmentNasopharyngeal Carcinoma1
2, 3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3RecruitingTreatmentOesophagogastric Cancer1
2, 3RecruitingTreatmentPancreatic Cancers1
2, 3RecruitingTreatmentTumor, Brain1
2, 3TerminatedTreatmentAnal Cancer1
3Active Not RecruitingNot AvailableBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity1
3Active Not RecruitingPreventionNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
3Active Not RecruitingTreatmentAdenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)2
3Active Not RecruitingTreatmentAnal Cancer1
3Active Not RecruitingTreatmentBladder Cancers2
3Active Not RecruitingTreatmentBladder Urothelial Carcinoma / Distal Urethral Carcinoma / Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma / Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Proximal Urethral Carcinoma / Recurrent Bladder Carcinoma / Recurrent Prostate Carcinoma / Recurrent Urethra Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Cancer / Stage IV Prostate Cancer / Stage IV Urethral Cancer / Ureter Carcinoma1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors4
3Active Not RecruitingTreatmentCancer of the Larynx / Cancer of the Nasal Cavity / Cancer of the Oral Cavity / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
3Active Not RecruitingTreatmentCancer, Ovarian1
3Active Not RecruitingTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
3Active Not RecruitingTreatmentCarcinoma of Unknown Primary1
3Active Not RecruitingTreatmentCervical Cancers2
3Active Not RecruitingTreatmentCervical Cancers / Uterine Cervical Cancer / Uterine Cervical Neoplasms1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentChildhood Embryonal Tumor / Childhood Extracranial Germ Cell Tumor / Childhood Extragonadal Germ Cell Tumor / Childhood Malignant Ovarian Germ Cell Tumor / Childhood Malignant Testicular Germ Cell Tumor / Childhood Teratoma / Ovarian Embryonal Carcinoma / Ovarian Yolk Sac Tumor / Stage II Malignant Testicular Germ Cell Tumor / Stage IIA Ovarian Germ Cell Tumor / Stage IIB Ovarian Germ Cell Tumor / Stage IIC Ovarian Germ Cell Tumor / Stage III Malignant Testicular Germ Cell Tumor / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIC Ovarian Germ Cell Tumor / Testicular Choriocarcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentEndometrial Cancers2
3Active Not RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IA Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEsophageal Cancers2
3Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers2
3Active Not RecruitingTreatmentEsophageal Squamous Cell Cancer1
3Active Not RecruitingTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentHead and Neck Cancers8
3Active Not RecruitingTreatmentHead and Neck Cancers / Precancerous Conditions1
3Active Not RecruitingTreatmentHepatocellular Carcinomas / Non-Resectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Osteosarcoma1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLung Cancers10
3Active Not RecruitingTreatmentLymphoma NOS4
3Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentNSCLC (Non-Small Cell Lung Cancer)1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma2
3Active Not RecruitingTreatmentNasopharyngeal Neoplasms1
3Active Not RecruitingTreatmentNeoplasms, Head and Neck1
3Active Not RecruitingTreatmentNeuroblastomas2
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
3Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentPancreatic Cancers1
3Active Not RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Major Salivary Gland Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
3Active Not RecruitingTreatmentRecurrent, Persistent or Metastasized Cervical Cancer1
3Active Not RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
3Active Not RecruitingTreatmentSmall Cell Lung Carcinoma1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3Active Not RecruitingTreatmentStage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
3Active Not RecruitingTreatmentStage I Lymphoepithelioma of the Nasopharynx / Stage I Squamous Cell Carcinoma of the Nasopharynx / Stage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentTumor, Brain / Tumors, Central Nervous System2
3Active Not RecruitingTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3CompletedPreventionCancers1
3CompletedSupportive CareAnemias / Cervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Radiation Toxicity / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer / Toxicity, Drug1
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdenocarcinomas1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
3CompletedTreatmentAnal Cancer2
3CompletedTreatmentAnemias / Head and Neck Cancers1
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentBrain and Central Nervous System Tumors1
3CompletedTreatmentCancer of Cervix1
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentCancer, Ovarian2
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer3
3CompletedTreatmentCarcinoma, Adrenal Cortical1
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer2
3CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
3CompletedTreatmentCervical Cancers5
3CompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
3CompletedTreatmentChildhood Hepatoblastoma / Recurrent Childhood Liver Cancer / Stage I Childhood Liver Cancer1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Testicular germ cell tumour1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentEndometrial Cancers3
3CompletedTreatmentEndometrial Cancers / Psychosocial Effects of Cancer and Its Treatment1
3CompletedTreatmentEsophageal Cancers4
3CompletedTreatmentEsophageal Cancers / Gastric Cancers1
3CompletedTreatmentEsophagus Cancer1
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
3CompletedTreatmentGastric Cancers10
3CompletedTreatmentGastric cancer stage IV1
3CompletedTreatmentHead and Neck Cancers10
3CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
3CompletedTreatmentLiver Cancer2
3CompletedTreatmentLocally Advanced Bladder Cancer1
3CompletedTreatmentLung Cancers16
3CompletedTreatmentLymphoma NOS3
3CompletedTreatmentMalignant Pleural Effusions1
3CompletedTreatmentMediastinal Cancer / Metastatic Cancers / Testicular germ cell tumour1
3CompletedTreatmentMelanoma (Skin)3
3CompletedTreatmentMelanoma / Skin Cancers1
3CompletedTreatmentMesothelioma, Malignant3
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentNeoplasms, Head and Neck2
3CompletedTreatmentNeoplasms, Lung1
3CompletedTreatmentNeuroblastomas3
3CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)4
3CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3CompletedTreatmentOral Cavity / Squamous Cell Carcinoma (SCC)1
3CompletedTreatmentPancreatic Cancers2
3CompletedTreatmentSarcomas2
3CompletedTreatmentSmall Cell Lung Cancer (SCLC)2
3CompletedTreatmentSmall Cell Lung Carcinoma1
3CompletedTreatmentSmall Cell Lung Carcinoma, Extensive Disease1
3CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentStage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3CompletedTreatmentStomach Cancer2
3CompletedTreatmentStomach Neoplasms1
3CompletedTreatmentTransitional Cell Carcinoma of Urinary Bladder1
3CompletedTreatmentTumor, Brain / Tumors, Central Nervous System1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3CompletedTreatmentUrinary Bladder Neoplasms1
3Enrolling by InvitationTreatmentBiliary Tract Cancer1
3Enrolling by InvitationTreatmentBladder Cancers1
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Germ Cell Cancer1
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Sex Cord Stromal Tumor1
3Enrolling by InvitationTreatmentCervical Cancers1
3Enrolling by InvitationTreatmentNasopharyngeal Carcinoma1
3Enrolling by InvitationTreatmentNasopharyngeal Neoplasms1
3Not Yet RecruitingNot AvailableHead and Neck Cancers1
3Not Yet RecruitingTreatmentCervical Cancers1
3Not Yet RecruitingTreatmentEsophageal Cancers / Esophageal Squamous Cell Carcinomas / Oesophageal Cancer1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentLaryngeal Squamous Cell Carcinoma Stage III / Laryngeal Squamous Cell Carcinoma Stage IV / Locally Advanced Malignant Neoplasm / Oropharyngeal Squamous Cell Carcinoma Stage III / Oropharyngeal Squamous Cell Carcinoma Stage IV / Squamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV1
3Not Yet RecruitingTreatmentLocally Advanced Cervical Cancer1
3Not Yet RecruitingTreatmentLung Cancers1
3Not Yet RecruitingTreatmentMalignant Hydrothorax / Non Small Cell Lung Cancer (NSCLC)1
3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
3Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Penis, Usual Type1
3RecruitingNot AvailableAdenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Non Epidermoid / Non-Small Cell Lung Cancer Metastatic / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingScreeningNeoplasms, Lung1
3RecruitingTreatment(FIGO Stage IIB-IVA) / Uterine Cervical Cancer1
3RecruitingTreatmentAdenocarcinoma of the Oesophago-gastric Junction / Adenocarcinoma of the Oesophagus / Junctional Tumours / Oesophageal Cancer / Oesophageal Tumours1
3RecruitingTreatmentAdvanced Non Small Cell Lung Cancer1
3RecruitingTreatmentBladder Cancers / Urothelial Cancer1
3RecruitingTreatmentCancer, Ovarian / Epithelial Ovarian Cancer / Fallopian Tube Cancer / Peritoneal Cancer1
3RecruitingTreatmentCarcinoma Cervix1
3RecruitingTreatmentCarcinoma, Small Cell1
3RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
3RecruitingTreatmentCarcinomas1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung1
3RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Chemotherapeutic Agent Toxicity / Cognitive Side Effects of Cancer Therapy / Psychological Impact of Cancer / Radiation Toxicity / Sexual Dysfunction and Infertility / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
3RecruitingTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Stage IA Cervical Cancer / Stage IB Cervical Cancer / Stage IIA Cervical Cancer1
3RecruitingTreatmentCervical Cancers8
3RecruitingTreatmentCervical Carcinoma Stage IIB1
3RecruitingTreatmentChemoradiotherapy / Enteral Nutrition Therapy / Esophageal Squamous Cell Carcinomas1
3RecruitingTreatmentChildhood Infratentorial Ependymoma / Childhood Supratentorial Ependymoma / Newly Diagnosed Childhood Ependymoma1
3RecruitingTreatmentChildhood Teratoma / Choriocarcinoma / Extragonadal Seminoma / Germ Cell Tumors / Germinoma / Malignant Germ Cell Neoplasm / Mixed Germ Cell Tumor / Non-seminomatous Germ Cell Tumors / Seminoma / Teratoma / Yolk Sac Tumor1
3RecruitingTreatmentCholangiocarcinomas / Gall Bladder Carcinoma1
3RecruitingTreatmentEffects of Chemotherapy / Stage IVC Nasopharyngeal Carcinoma1
3RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3RecruitingTreatmentEsophageal Cancers3
3RecruitingTreatmentEsophageal Squamous Cell Carcinomas1
3RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentGastric Adenocarcinoma1
3RecruitingTreatmentGastric Cancers5
3RecruitingTreatmentGastric cancer stage IV1
3RecruitingTreatmentGastroesophageal Junction Adenocarcinoma / Metastatic Gastric Adenocarcinoma1
3RecruitingTreatmentGerm Cell Tumors1
3RecruitingTreatmentHPV Positive Oropharyngeal Squamous Cell Carcinoma1
3RecruitingTreatmentHead and Neck Cancers1
3RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3RecruitingTreatmentHilar Cholangiocarcinoma1
3RecruitingTreatmentLiver Cancer / Ototoxicity1
3RecruitingTreatmentLocal Advanced Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentLocally Advanced Head and Neck Cancer1
3RecruitingTreatmentLocally Advanced Head and Neck HPV Negative Squamous Cell Cancers1
3RecruitingTreatmentLung Cancers2
3RecruitingTreatmentLymphoma NOS1
3RecruitingTreatmentMelanoma1
3RecruitingTreatmentMesothelioma2
3RecruitingTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
3RecruitingTreatmentMetastatic Non-Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentNasopharyngeal Carcinoma8
3RecruitingTreatmentNeoplasms, Esophageal1
3RecruitingTreatmentNeoplasms, Head and Neck2
3RecruitingTreatmentNeoplasms, Oropharyngeal1
3RecruitingTreatmentNeuroblastomas2
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small Cell Lung Cancer Metastatic / Non-Small Cell Lung Cancer Stage IIIB2
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer3
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3RecruitingTreatmentOropharyngeal Squamous Cell Carcinoma1
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3RecruitingTreatmentProsthesis Survival1
3RecruitingTreatmentSeminoma / Testicular Neoplasms1
3RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
3RecruitingTreatmentStage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3RecruitingTreatmentStage III Intrahepatic Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma1
3RecruitingTreatmentThymoma and Thymic Carcinoma1
3RecruitingTreatmentTransitional Cell Carcinoma of Ureter1
3RecruitingTreatmentUrothelial Carcinoma Associated 1 RNA, Human1
3RecruitingTreatmentUterine Sarcoma1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3SuspendedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3TerminatedPreventionHepatocellular Carcinomas / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Liver / Recurrences1
3TerminatedSupportive CareHead and Neck Cancers / Mucositis / Pain / Radiation Toxicity1
3TerminatedTreatmentBladder Cancers2
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentCancer, Ovarian1
3TerminatedTreatmentCervical Cancers2
3TerminatedTreatmentEndometrial Cancers1
3TerminatedTreatmentEsophageal Cancers1
3TerminatedTreatmentExtensive Disease / First-Line / Small Cell Lung Cancer (SCLC)1
3TerminatedTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3TerminatedTreatmentGastric Cancers3
3TerminatedTreatmentHead and Neck Cancers2
3TerminatedTreatmentHead and Neck Cancers / Squamous Cell Carcinoma (SCC)1
3TerminatedTreatmentLung Cancers4
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentNeoplasms, Esophageal / Squamous Cell Cancer1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentSarcomas1
3TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1
3TerminatedTreatmentVulvar Cancers1
3WithdrawnTreatmentCarcinomas / Head and Neck Cancers1
3WithdrawnTreatmentCervical Cancers1
3WithdrawnTreatmentEsophageal Cancers1
3WithdrawnTreatmentHead and Neck Cancers1
3WithdrawnTreatmentHepatocellular Carcinomas1
3WithdrawnTreatmentLocalized Resectable Adult Primary Liver Cancer / Stage III Childhood Liver Cancer1
3WithdrawnTreatmentLung Cancers1
3WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
4Active Not RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
4CompletedNot AvailableNonsmall Cell Lung Cancer / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
4CompletedSupportive CareAnemias / Cervical Cancers1
4CompletedTreatmentNeoplasms, Head and Neck1
4CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
4CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
4CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
4RecruitingTreatmentAdvanced Lung Squamous Carcinoma1
4RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
4RecruitingTreatmentPatients With Head and Neck Cancer (ORL)1
4RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
4RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
Not AvailableActive Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
Not AvailableActive Not RecruitingTreatmentBrain and Central Nervous System Tumors1
Not AvailableActive Not RecruitingTreatmentCervical Cancers1
Not AvailableActive Not RecruitingTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableActive Not RecruitingTreatmentHead and Neck Cancers1
Not AvailableActive Not RecruitingTreatmentLung Cancers1
Not AvailableActive Not RecruitingTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableActive Not RecruitingTreatmentNeuroblastomas1
Not AvailableActive Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableActive Not RecruitingTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableAvailableNot AvailableMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation / Triple-Negative Breast Cancer (TNBC)1
Not AvailableCompletedNot AvailableCervical Intraepithelial Neoplasias2
Not AvailableCompletedNot AvailableOsteosarcomas / Spindle Cell Sarcoma of Bone1
Not AvailableCompletedNot AvailableSmall Cell Lung Cancer (SCLC)1
Not AvailableCompletedDiagnosticEsophageal Cancers / Gastric Cancers1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentSarcomas1
Not AvailableCompletedTreatmentUterine Cervical Neoplasms1
Not AvailableNot Yet RecruitingNot AvailableHead and Neck Cancers1
Not AvailableNot Yet RecruitingTreatmentNasopharyngeal Carcinoma1
Not AvailableNot Yet RecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableRecruitingNot AvailableHormone Refractory Prostate Cancer1
Not AvailableRecruitingNot AvailableMalnutrition / Nasopharyngeal Carcinoma1
Not AvailableRecruitingNot AvailableNon Small Cell Lung Cancer (NSCLC)1
Not AvailableRecruitingSupportive CareNeoplasms, Malignant / Ototoxicity1
Not AvailableRecruitingTreatmentBladder Cancers / Epirubicin Instillation / Gemcitabine and Cisplatin Chemotherapy / Prognosis / Recurrences1
Not AvailableRecruitingTreatmentCervical Cancers1
Not AvailableRecruitingTreatmentCervical Cancers / Uterine Cancers1
Not AvailableRecruitingTreatmentChemotherapy, Adjuvant / Hepatocellular Carcinomas / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentEsophageal Cancers / Gastric Cancers1
Not AvailableRecruitingTreatmentHepatocellular Carcinomas1
Not AvailableRecruitingTreatmentIntrahepatic Cholangiocarcinoma1
Not AvailableRecruitingTreatmentMedulloblastomas1
Not AvailableRecruitingTreatmentNeuroblastomas1
Not AvailableRecruitingTreatmentPleural Effusion, Malignant1
Not AvailableRecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Cancer / Recurrent Uterine Corpus Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cavity Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
Not AvailableRecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
Not AvailableRecruitingTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Tongue Cancer1
Not AvailableSuspendedSupportive CareMalignant Ovarian Mixed Epithelial Tumor / Nausea and Vomiting / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
Not AvailableSuspendedTreatmentChemotherapeutic Agent Toxicity / Renal Toxicity / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedPreventionCancers1
Not AvailableTerminatedTreatmentEpithelial Ovarian Cancer / Fallopian Tube Carcinoma1
Not AvailableTerminatedTreatmentHead and Neck Squamous Cell Cancer1
Not AvailableTerminatedTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableTerminatedTreatmentOsteosarcomas1
Not AvailableTerminatedTreatmentResectable Intrahepatic Cholangiocarcinoma / Unresectable Intrahepatic Cholangiocarcinoma1
Not AvailableWithdrawnTreatmentHead and Neck Cancers1
Not AvailableWithdrawnTreatmentParanasal Sinus Neoplasms1
PharmacodynamicsCisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.
Mechanism of actionAlkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
AbsorptionFollowing cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.
Volume of distribution

Volume of distribution at steady state = 11-12 L/m^2

Protein bindingCisplatin does not undergo instantaneous and reversible binding to plasma protein that is characteristic of normal drug-protein binding. However, the platinum itself is capable of binding to plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound.
MetabolismNot Available
Route of eliminationThe parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.
Half lifeCisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2. Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.
Clearance
  • 15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2]
  • 62 mL/min/m^2 [renal clearance, 2-hour infusion of 100 mg/m^2]
  • 50 mL/min/m^2 [renal clearance, 6- to 7-hour infusion of 100 mg/m^2]
    The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Glutathione S-transferase Mu 1
Gene symbol: GSTM1
UniProt: P09488
Not AvailableGSTM1presenceTinnitus, hearing impairment, Raynaud syndrome18162130
Low-density lipoprotein receptor-related protein 2
Gene symbol: LRP2
UniProt: P98164
rs2075252 Not AvailableA alleleOtotoxicity (hearing loss)17457342
Low-density lipoprotein receptor-related protein 2
Gene symbol: LRP2
UniProt: P98164
rs4668123 Not AvailableT alleleOtotoxicity (hearing loss)17457342
Glutathione S-transferase P
Gene symbol: GSTP1
UniProt: P09211
rs1695 Not AvailableA alleleTinnitus, hearing impairment, Raynaud syndrome18162130
DNA repair protein complementing XP-C cells
Gene symbol: XPC
UniProt: Q01831
rs2228001 Not AvailableG > TThose with the GG or GT genotpe have an increase risk of adverse effects21047201
Interactions
Drug Interactions
DrugInteractionDrug group
AcetaminophenThe serum concentration of Cisplatin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
AclarubicinCisplatin may increase the nephrotoxic activities of Aclarubicin.Investigational
AfatinibThe serum concentration of Cisplatin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Cisplatin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Cisplatin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Cisplatin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Cisplatin can be increased when it is combined with Alfentanil.Approved, Illicit
ALT-110The risk or severity of adverse effects can be increased when Cisplatin is combined with ALT-110.Investigational
AmantadineThe serum concentration of Cisplatin can be increased when it is combined with Amantadine.Approved
AmikacinCisplatin may increase the nephrotoxic activities of Amikacin.Approved, Vet Approved
Aminohippuric acidThe serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Cisplatin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Cisplatin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Cisplatin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Cisplatin can be decreased when it is combined with Amprenavir.Approved
AmrubicinCisplatin may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
AmsacrineThe serum concentration of Cisplatin can be increased when it is combined with Amsacrine.Approved
annamycinCisplatin may increase the nephrotoxic activities of annamycin.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Cisplatin.Investigational
ApramycinCisplatin may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ArbekacinCisplatin may increase the nephrotoxic activities of Arbekacin.Approved
AstemizoleThe serum concentration of Cisplatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Cisplatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Cisplatin can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Cisplatin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Cisplatin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Cisplatin can be increased when it is combined with Azithromycin.Approved
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Cisplatin.Investigational
BenzocaineThe serum concentration of Cisplatin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Cisplatin can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
BiperidenThe serum concentration of Cisplatin can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Cisplatin can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Cisplatin can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideBumetanide may increase the nephrotoxic activities of Cisplatin.Approved
BuprenorphineThe serum concentration of Cisplatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Cisplatin can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Cisplatin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelCisplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CaffeineThe serum concentration of Cisplatin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Cisplatin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Cisplatin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Cisplatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Cisplatin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Cisplatin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Cisplatin can be increased when it is combined with Caspofungin.Approved
CDX-110The risk or severity of adverse effects can be increased when Cisplatin is combined with CDX-110.Investigational
ChloroquineThe serum concentration of Cisplatin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Cisplatin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Cisplatin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Cisplatin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Cisplatin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Cisplatin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Cisplatin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cisplatin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Cisplatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Cisplatin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Cisplatin can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Cisplatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Cisplatin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Cisplatin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Clozapine.Approved
CobicistatThe serum concentration of Cisplatin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Cisplatin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Cisplatin can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Cisplatin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
CyclosporineThe serum concentration of Cisplatin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Cisplatin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Cisplatin can be increased when it is combined with Dactinomycin.Approved
DasatinibThe serum concentration of Cisplatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinCisplatin may increase the nephrotoxic activities of Daunorubicin.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.Approved
DesipramineThe serum concentration of Cisplatin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cisplatin.Approved
DesloratadineThe serum concentration of Cisplatin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Cisplatin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Cisplatin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Cisplatin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Cisplatin.Approved
DihydroergotamineThe serum concentration of Cisplatin can be increased when it is combined with Dihydroergotamine.Approved
DihydrostreptomycinCisplatin may increase the nephrotoxic activities of Dihydrostreptomycin.Vet Approved
DiltiazemThe serum concentration of Cisplatin can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Cisplatin can be increased when it is combined with Dipyridamole.Approved
DocetaxelCisplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
DoxazosinThe serum concentration of Cisplatin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Cisplatin can be increased when it is combined with Doxepin.Approved
DoxorubicinCisplatin may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Cisplatin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Cisplatin can be increased when it is combined with Dronedarone.Approved
ElbasvirThe serum concentration of Cisplatin can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Cisplatin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Cisplatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Cisplatin can be increased when it is combined with Enzalutamide.Approved
EpirubicinCisplatin may increase the nephrotoxic activities of Epirubicin.Approved
ErgonovineThe serum concentration of Cisplatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Cisplatin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Cisplatin can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Cisplatin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Cisplatin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Cisplatin can be decreased when it is combined with Estrone.Approved
Etacrynic acidEtacrynic acid may increase the nephrotoxic activities of Cisplatin.Approved
EtoposideThe serum concentration of Cisplatin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Cisplatin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Cisplatin can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Cisplatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Cisplatin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Cisplatin can be increased when it is combined with Fidaxomicin.Approved
FingolimodCisplatin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Cisplatin can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Cisplatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Cisplatin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Cisplatin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Cisplatin can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Cisplatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Cisplatin.Approved
FramycetinCisplatin may increase the nephrotoxic activities of Framycetin.Approved
FurosemideFurosemide may increase the nephrotoxic activities of Cisplatin.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Cisplatin is combined with G17DT.Investigational
GefitinibThe serum concentration of Cisplatin can be increased when it is combined with Gefitinib.Approved, Investigational
GeneticinCisplatin may increase the nephrotoxic activities of Geneticin.Experimental
GenisteinThe serum concentration of Cisplatin can be increased when it is combined with Genistein.Investigational
GentamicinCisplatin may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1ACisplatin may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GI-5005The risk or severity of adverse effects can be increased when Cisplatin is combined with GI-5005.Investigational
GlyburideThe serum concentration of Cisplatin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Cisplatin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Cisplatin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Cisplatin can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Cisplatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hygromycin BCisplatin may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IdarubicinCisplatin may increase the nephrotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Cisplatin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Cisplatin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Cisplatin can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Cisplatin can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Cisplatin can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Cisplatin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cisplatin is combined with INGN 225.Investigational
INNO-206Cisplatin may increase the nephrotoxic activities of INNO-206.Investigational
IsavuconazoniumThe serum concentration of Cisplatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Cisplatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cisplatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Cisplatin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KanamycinCisplatin may increase the nephrotoxic activities of Kanamycin.Approved, Vet Approved
KetamineThe serum concentration of Cisplatin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Cisplatin can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Cisplatin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Cisplatin can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Cisplatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Cisplatin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Cisplatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Cisplatin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Cisplatin can be decreased when it is combined with Liotrix.Approved
Lipoic AcidThe therapeutic efficacy of Cisplatin can be decreased when used in combination with Lipoic Acid.Approved, Nutraceutical
LisinoprilThe serum concentration of Cisplatin can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Cisplatin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Cisplatin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Cisplatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Cisplatin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Cisplatin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Cisplatin can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Cisplatin can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Cisplatin can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Cisplatin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Cisplatin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Cisplatin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Cisplatin can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cisplatin.Withdrawn
MethadoneThe serum concentration of Cisplatin can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Cisplatin can be increased when it is combined with Metoprolol.Approved, Investigational
MetrizamideCisplatin may increase the nephrotoxic activities of Metrizamide.Approved
MibefradilThe serum concentration of Cisplatin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Cisplatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Cisplatin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Cisplatin can be decreased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Cisplatin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Cisplatin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Cisplatin can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Cisplatin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Cisplatin can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.Approved, Investigational
NeamineCisplatin may increase the nephrotoxic activities of Neamine.Experimental
NefazodoneThe serum concentration of Cisplatin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Cisplatin can be decreased when it is combined with Nelfinavir.Approved
NeomycinCisplatin may increase the nephrotoxic activities of Neomycin.Approved, Vet Approved
NeostigmineThe serum concentration of Cisplatin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetilmicinCisplatin may increase the nephrotoxic activities of Netilmicin.Approved
NicardipineThe serum concentration of Cisplatin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Cisplatin can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Cisplatin can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Cisplatin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Cisplatin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Cisplatin can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Cisplatin can be decreased when it is combined with Norethisterone.Approved
OmeprazoleThe serum concentration of Cisplatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Cisplatin.Approved
P-NitrophenolThe serum concentration of Cisplatin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelCisplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Cisplatin can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Cisplatin can be increased when it is combined with Pantoprazole.Approved
ParomomycinCisplatin may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Cisplatin can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Cisplatin can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Cisplatin can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Cisplatin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.Approved, Investigational
PimozideThe serum concentration of Cisplatin can be increased when it is combined with Pimozide.Approved
PirarubicinCisplatin may increase the nephrotoxic activities of Pirarubicin.Investigational
PiretanidePiretanide may increase the nephrotoxic activities of Cisplatin.Experimental
Platelet Activating FactorThe serum concentration of Cisplatin can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinCisplatin may increase the nephrotoxic activities of Plicamycin.Approved, Withdrawn
PonatinibThe serum concentration of Cisplatin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Cisplatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Cisplatin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Cisplatin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Cisplatin can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Cisplatin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Cisplatin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Cisplatin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Cisplatin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Cisplatin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Cisplatin can be increased when it is combined with Protriptyline.Approved
PuromycinCisplatin may increase the nephrotoxic activities of Puromycin.Experimental
QuercetinThe serum concentration of Cisplatin can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Cisplatin can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Cisplatin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Cisplatin can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cisplatin.Approved
RanitidineThe serum concentration of Cisplatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Cisplatin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Cisplatin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Cisplatin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Cisplatin can be decreased when it is combined with Reserpine.Approved
RibostamycinCisplatin may increase the nephrotoxic activities of Ribostamycin.Approved
RifampicinThe serum concentration of Cisplatin can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Cisplatin can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Cisplatin can be decreased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Cisplatin.Approved
RolapitantThe serum concentration of Cisplatin can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Cisplatin can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Cisplatin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Cisplatin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Cisplatin can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Cisplatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Cisplatin can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.Approved
SirolimusThe serum concentration of Cisplatin can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinCisplatin may increase the nephrotoxic activities of Sisomicin.Investigational
SorafenibThe serum concentration of Cisplatin can be increased when it is combined with Sorafenib.Approved, Investigational
SP1049CCisplatin may increase the nephrotoxic activities of SP1049C.Investigational
SpectinomycinCisplatin may increase the nephrotoxic activities of Spectinomycin.Approved, Vet Approved
SpironolactoneThe serum concentration of Cisplatin can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Cisplatin is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Cisplatin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Cisplatin can be increased when it is combined with Staurosporine.Experimental
StreptomycinCisplatin may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
StreptozocinCisplatin may increase the nephrotoxic activities of Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Cisplatin can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Cisplatin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Cisplatin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Cisplatin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cisplatin.Approved, Investigational
TacrolimusThe serum concentration of Cisplatin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Cisplatin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Cisplatin can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Cisplatin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Cisplatin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Cisplatin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Cisplatin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Cisplatin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Cisplatin can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Cisplatin is combined with TG4010.Investigational
TicagrelorThe serum concentration of Cisplatin can be increased when it is combined with Ticagrelor.Approved
TobramycinCisplatin may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TofacitinibCisplatin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Cisplatin can be increased when it is combined with Tolvaptan.Approved
TopotecanThe risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.Approved, Investigational
TorasemideTorasemide may increase the nephrotoxic activities of Cisplatin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
TrazodoneThe serum concentration of Cisplatin can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Cisplatin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Cisplatin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Cisplatin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Cisplatin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Cisplatin can be increased when it is combined with Troleandomycin.Approved
ValrubicinCisplatin may increase the nephrotoxic activities of Valrubicin.Approved
VenlafaxineThe serum concentration of Cisplatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Cisplatin can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Cisplatin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Cisplatin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Cisplatin can be increased when it is combined with Zimelidine.Withdrawn
ZorubicinCisplatin may increase the nephrotoxic activities of Zorubicin.Experimental
Food Interactions
  • Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.
References
Synthesis Reference

Murray A. Kaplan, Alphonse P. Granatek, “Process for the preparation of microcrystalline cisplatin.” U.S. Patent US4322391, issued March 30, 1982.

US4322391
General ReferencesNot Available
External Links
ATC CodesL01XA01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (413 KB)
MSDSDownload (76.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9637
Blood Brain Barrier+0.9469
Caco-2 permeable-0.5704
P-glycoprotein substrateNon-substrate0.8714
P-glycoprotein inhibitor INon-inhibitor0.9763
P-glycoprotein inhibitor IINon-inhibitor0.9843
Renal organic cation transporterNon-inhibitor0.9211
CYP450 2C9 substrateNon-substrate0.8069
CYP450 2D6 substrateNon-substrate0.7874
CYP450 3A4 substrateNon-substrate0.7495
CYP450 1A2 substrateNon-inhibitor0.7733
CYP450 2C9 inhibitorNon-inhibitor0.7808
CYP450 2D6 inhibitorNon-inhibitor0.9075
CYP450 2C19 inhibitorNon-inhibitor0.7995
CYP450 3A4 inhibitorNon-inhibitor0.8562
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9204
Ames testNon AMES toxic0.5661
CarcinogenicityCarcinogens 0.5146
BiodegradationNot ready biodegradable0.9213
Rat acute toxicity2.7612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Non-inhibitor0.9344
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmachemie bv
  • Teva parenteral medicines inc
  • Bristol myers co
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous1 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous100 mg/100mL
Injection, solutionIntravenous50 mg/50mL
LiquidIntravenous.5 mg
LiquidIntravenous1 mg
SolutionIntravenous1.0 mg
SolutionIntravenous1 mg
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Prices
Unit descriptionCostUnit
Cisplatin 1 mg/ml vial0.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 dec °CPhysProp
water solubility2530 mg/L (at 25 °C)AMUNDSEN,AR & STERN,EW (1982)
logP-2.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
logP0.041ChemAxon
pKa (Strongest Basic)5.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.04 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity22.84 m3·mol-1ChemAxon
Polarizability10.31 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a transition metal.
KingdomChemical entities
Super ClassInorganic compounds
ClassMixed metal/non-metal compounds
Sub ClassTransition metal salts
Direct ParentTransition metal chlorides
Alternative Parents
Substituents
  • Transition metal chloride
  • Inorganic chloride salt
  • Inorganic salt
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Garcia Sar D, Montes-Bayon M, Aguado Ortiz L, Blanco-Gonzalez E, Sierra LM, Sanz-Medel A: In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal Bioanal Chem. 2008 Jan;390(1):37-44. Epub 2007 Oct 12. [PubMed:17932658 ]
  4. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG: Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol. 2007 Nov 9;373(5):1123-40. Epub 2007 Aug 23. [PubMed:17900616 ]
  5. Bloemink MJ, Reedijk J: Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst. 1996;32:641-85. [PubMed:8640534 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. doi: 10.1016/j.rvsc.2009.09.002. Epub 2009 Oct 8. [PubMed:19818462 ]
  2. Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, Yildirim Z: Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol. 2004 Jan-Feb;24(1):27-35. [PubMed:14745844 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular Weight:
146422.99 Da
References
  1. Yilmaz HR, Sogut S, Ozyurt B, Ozugurlu F, Sahin S, Isik B, Uz E, Ozyurt H: The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health. 2005 May;21(3-4):67-73. [PubMed:15986578 ]
  2. Cetin R, Devrim E, Kilicoglu B, Avci A, Candir O, Durak I: Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol. 2006 Jan-Feb;26(1):42-6. [PubMed:16158393 ]
  3. Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. doi: 10.1016/j.rvsc.2009.09.002. Epub 2009 Oct 8. [PubMed:19818462 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Nakamura M, Imaoka S, Tanaka E, Misawa S, Funae Y: cis-Diamminedichloroplatinum induces peroxisomes as well as CYP4A1 in rat kidney. Res Commun Mol Pathol Pharmacol. 1998 Jan;99(1):23-32. [PubMed:9523352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Tusgaard B, Norregaard R, Jensen AM, Wang G, Topcu SO, Wang Y, Nielsen S, Frokiaer J: Cisplatin decreases renal cyclooxygenase-2 expression and activity in rats. Acta Physiol (Oxf). 2011 May;202(1):79-90. doi: 10.1111/j.1748-1716.2011.02257.x. Epub 2011 Mar 22. [PubMed:21272267 ]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
Actions
inhibitor
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
nat
Uniprot ID:
P0A5L8
Molecular Weight:
Not Available
References
  1. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, Dupret JM, Rodrigues-Lima F: Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol. 2008 Jun;73(6):1761-8. doi: 10.1124/mol.108.045328. Epub 2008 Feb 29. [PubMed:18310302 ]
  2. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30. [PubMed:15229296 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009 Jun;20(5):305-11. [PubMed:19378397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009 Jun;20(5):305-11. [PubMed:19378397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Bodur E: Human serum butyrylcholinesterase interactions with cisplatin and cyclophosphamide. Biochimie. 2010 Aug;92(8):979-84. doi: 10.1016/j.biochi.2010.04.010. Epub 2010 Apr 24. [PubMed:20417682 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Acts on 1,2-epoxy-3-(4-nitrophenoxy)propane, phenethylisothiocyanate 4-nitrobenzyl chloride and 4-nitrophenethyl bromide. Displays glutathione peroxidase activity with cumene hydroperoxide.
Gene Name:
GSTT1
Uniprot ID:
P30711
Molecular Weight:
27334.755 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name:
MT1A
Uniprot ID:
P04731
Molecular Weight:
6120.19 Da
References
  1. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Dam WA, Sleijfer DT, Mulder NH: Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. [PubMed:10709094 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name:
MT2A
Uniprot ID:
P02795
Molecular Weight:
6042.05 Da
References
  1. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Dam WA, Sleijfer DT, Mulder NH: Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. [PubMed:10709094 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
Gene Name:
SOD1
Uniprot ID:
P00441
Molecular Weight:
15935.685 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
S-nitrosoglutathione binding
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name:
GSTP1
Uniprot ID:
P09211
Molecular Weight:
23355.625 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Superoxide dismutase activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO1
Uniprot ID:
P15559
Molecular Weight:
30867.405 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTM1
Uniprot ID:
P09488
Molecular Weight:
25711.555 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
  2. Demeule M, Brossard M, Beliveau R: Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol. 1999 Dec;277(6 Pt 2):F832-40. [PubMed:10600929 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855 ]
  2. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA: Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8. [PubMed:20067471 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Copper uptake transmembrane transporter activity
Specific Function:
High-affinity, saturable copper transporter involved in dietary copper uptake.
Gene Name:
SLC31A1
Uniprot ID:
O15431
Molecular Weight:
21090.545 Da
References
  1. Howell SB, Safaei R, Larson CA, Sailor MJ: Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. [PubMed:20159940 ]
  2. Kurokawa T, He G, Siddik ZH: Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol. 2010 Feb;65(3):427-36. doi: 10.1007/s00280-009-1045-2. Epub 2009 Jun 16. [PubMed:19529937 ]
  3. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB: Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res. 2009 Jan 15;15(2):553-60. doi: 10.1158/1078-0432.CCR-08-2081. [PubMed:19147760 ]
  4. Liang ZD, Stockton D, Savaraj N, Tien Kuo M: Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol. 2009 Oct;76(4):843-53. doi: 10.1124/mol.109.056416. Epub 2009 Jul 1. [PubMed:19570948 ]
  5. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134 ]
  6. Pabla N, Murphy RF, Liu K, Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11. doi: 10.1152/ajprenal.90545.2008. Epub 2009 Jan 14. [PubMed:19144690 ]
  7. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668 ]
  8. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30. [PubMed:15229296 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Copper ion transmembrane transporter activity
Specific Function:
Involved in low-affinity copper uptake.
Gene Name:
SLC31A2
Uniprot ID:
O15432
Molecular Weight:
15681.29 Da
References
  1. Blair BG, Larson CA, Safaei R, Howell SB: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9. [PubMed:19509135 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).Isoform 2: Inhibits TNF-alpha-mediated apoptosis through blocking one or more caspases.
Gene Name:
ABCC6
Uniprot ID:
O95255
Molecular Weight:
164904.81 Da
References
  1. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Copper-exporting atpase activity
Specific Function:
Involved in the export of copper out of the cells, such as the efflux of hepatic copper into the bile.
Gene Name:
ATP7B
Uniprot ID:
P35670
Molecular Weight:
157261.34 Da
References
  1. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134 ]
  2. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26. [PubMed:19470734 ]
  3. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Superoxide dismutase copper chaperone activity
Specific Function:
May supply copper to copper-requiring proteins within the secretory pathway, when localized in the trans-Golgi network. Under conditions of elevated extracellular copper, it relocalized to the plasma membrane where it functions in the efflux of copper from cells.
Gene Name:
ATP7A
Uniprot ID:
Q04656
Molecular Weight:
163372.275 Da
References
  1. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134 ]
  2. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F: Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52. doi: 10.1016/j.tiv.2008.09.001. Epub 2008 Sep 9. [PubMed:18801423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23